Administrative Office
Richmond, Virginia, 23219, United States
NCT Number: NCT07661823
BRIEF SUMMARY
A. "What is the purpose of this study?"
This study will test whether the "AI City Hall Project" (QAIAx), a quantum artificial intelligence (AI) public health agency, can provide free or low-cost behavioral and mental health services inside self-contained, dome-enclosed communities called "Microcities". Researchers want to see if AI-managed public administration, AI humanoid robots, holoportation of human-figures via 'holo-suites' (e.g., AI-119 Kikkeri Holo-Suit; AI-119 Vulcan QM-Ware) and advanced AI mental-health tools can lower housing and care costs, improve mental health outcomes (e.g., particular ecosystems using AI tools among persons with one or more addiction disorders), and be financially sustainable for people on fixed incomes or public assistance.
B. "What conditions does the study focus on?"
The study focuses on adults with:
* Autism spectrum disorders (Asperger's, autism, ADHD, ASD) * Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA/ecstasy, tobacco/nicotine) * Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders) * Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).
C. "What does the study involve?"
Eligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital "attitude inoculation" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.
**Who can participate?**
You may be able to join if you:
* Are an adult (18 years or older) * Have a diagnosis of one of the listed mental-health or addiction disorders * Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organisation (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole/probation officer, judge) * Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.
Participants who are veterans, receive public assistance (e.g., VA disability, SSDI/SSI, Medicaid, Medicare), or are experiencing homelessness may be prioritised.
**Where is the study taking place?** The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.
**Who is sponsoring the study?** The study is sponsored by **Veterans Recovery Network Inc.**, a non-profit organization, in collaboration with **AI-119 Vulcan Project Research & Educational Technology Co. (PRETCO)** and an AI legal agency. The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §129a) and is part of a Cooperative Research and Development Agreement (CRADA) with U.S. Special Operations Command (USSOCOM).
This summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.
Trial opening soon.
Get Notified17 year–99 year
All sexes
Interventional
Not applicable
Richmond, Virginia, 23219, United States
I. MEMBER PLATFORM OVERVIEW
The QAIAx platform operates a dual-framework infrastructure consisting of a commercial (US-based) quantum AI cloud-robotics layer and an RDT&E clinical research layer. Program participants are required to maintain active trainee, member, or intern status with the sponsoring organization, which includes a standard and premium monthly platform membership subscription, or QAIAx ecosystem site called a (QAIAx) 'microcity' (a sponsored member-organization community where RDT&E is held). This commercial fee provides standard access to a peer-to-peer access to virtual and physical 'holo-suites' via omni-AI humanoid, quantum AI agent (generative AI human-like avatar as a holographic/audio/visual bot controlled via remote LLM command point) or QAIAx microcity administrative via a cloud server sandbox for independent learning machine studies and P2P tech support. This membership constraint serves strictly as an organizational prerequisite for ecosystem access and is completely decoupled from the clinical trial protocol. No fee is charged to subjects for participating in the clinical research arms, or for accessing the patented experimental interventions (AI-119 / AI Wat '1498' utility patent series). For eligible applicants qualifying as low-income or homeless ADA/SSDI, military veterans, personnel of a state/federal government agency, or enrolled student of an accredited post-secondary school, the physical Omni-AI Microcity housing arms, standard platform subscription fees may qualify for a fully/partially sponsored or waived by the authorized non-governmental organization (NGO) for the duration of the trial monitoring period and full member subscription that aligns with an affiliated health services program or educational learning track program to ensure zero financial cost to the research subject.
II. PLATFORM & EQUIPMENT LEGAL AUTHORITIES.
Brief Summary of Data Sharing, Export Compliance, and Intellectual Property Restraints (Pursuant to the U.S. and EU laws)
This Cooperative Agreement acknowledges that the use of AI humanoids for U.S. Government-funded RDT&E is tightly governed by overlapping U.S. export control, intellectual property, and national security laws, with specific restrictions that also inform compliance under analogous EU frameworks.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64/074,526, 64/063,557, 63/903,181, 63/729,428: A quantum AI public health agency that provides free public health services to registered and sponsored visitors/occupants for RDT&E under 28 U.S. Code 1498 (classified as a PPA under 10 U.S. Code 129a). AI Public Health Central Microcity will focus on behavioral and psychiatric health for patients with various common mental health and addiction disorders, placed in monitored ecosystems with AI/AGI tools managing public administration resources under statistical surveys to determine to determine which fiscal viability, effectiveness and accuracy AI/AGI Health tools for mental health treatment (e.g., AI robotics; 'Quasi-Mind Ware' and Mental Health/Psychiatric Cyber-Medicine treatment applying AI Symbiosis, e.g., See 'Traum-to-Real' installation of generative AI memory into the human mind via attitude inoculation)
QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64/074,526, 64/063,557, 63/903,181, 63/729,428: A quantum AI public health agency that provides free public health services to registered and sponsored visitors/occupants for RDT&E under 28 U.S. Code 1498 (classified as a PPA under 10 U.S. Code 129a)
Time frame: Baseline enrollment, month 12, and month 24 (tracked monthly)
This comprehensive description bridges the clinical parameters of the AI-119 Vulcan SOF Program (an AGI/AI Ecosystems RDT&E Program launched under the 119th U.S. Congress) and Veterans Recovery Network Program (VA-authorized program, est. 2020, Richmond VAMC) with the high-velocity public, private, and military administrative functions optimized by the AI-119 and AI Wat patent series under 28 U.S.C. § 1498 (Government Use of Patents), using a Omni-AI robotics among Holo-Suit, Quasi-Mind Ware (QM-Ware), Body-Ware, QAIA Humanoid (via "AI-Me" Hybrid AI Symbiote app). This primary outcome measures the definitive capacity of the Vulcan QAIAx v4.0x (Beta ISAC) autonomous platform to generate an efficient lifestyle, stabilize severe psychiatric and addiction disorders, and optimize administrative resource delivery across Private, Public, and Military sector frameworks. Utilizing a '90/10' hybrid workforce model (90% omni-AI Humanoid Workforce / 10% Human Auditor & Administrator oversight).
Time frame: Baseline enrollment, month 12, and month 24 (tracked monthly)
The primary outcome directly track the core clinical and lifestyle stabilization of the veterans residing in the monitored Microcity ecosystem, measuring the effectiveness of the advanced AI/AGI tools. Total duration (measured in months vs. the traditional multi-year trajectories) and accuracy rate of AI-driven legal/health document processing, error corrections, and intake evaluations managed by the 90% AI Humanoid Workforce under human auditor ethical oversight under 'Kikkeri doctrine' to 'hire a million to skill a billion.'
Time frame: Baseline enrollment, month 12, and month 24 (tracked monthly)
Total financial variance and cost-mitigation rates achieved by housing occupants within the $100 to $2,000 per month extreme-affordability bracket (including digital device provisioning and logistics integration), evaluated against standard public healthcare and federal housing expenditure benchmarks.
Contact information is provided by the study sponsor or research team.
C Peterson
CONTACT
RDTE Administrator
CONTACT
Veterans Recovery Network Inc.
Other
QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App No(s). 64/105,164, 64/074,526, 64/063,557, 63/903,181, 63/729,428: A Quantum AI Public Health Agency That Provides Free Public Health Services to Registered and Sponsored Visitors/Occupants for RDT&E Under 28 U.S. Code 1498 (Classified as a PPA Under 10 U.S. Code 129a)
Acronym: QAIAx
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00844753
Asperger Syndrome, Asperger's Disorder
Rochester, New York, United States
View Trial DetailsNCT01631851
Aberrant Motor Behavior in Dementia, Aggression
New Haven, Connecticut, United States
View Trial DetailsNCT01592747
Asperger Syndrome, Asperger's Disorder
Dothan, Alabama, United States
View Trial DetailsNCT00308074
Aberrant Motor Behavior in Dementia, Aggression
Medford, Massachusetts, United States
View Trial Details